Royalty Pharma (RPRX) Interest Expenses (2019 - 2026)

Royalty Pharma (RPRX) has 8 years of Interest Expenses data on file, last reported at $223.6 million in Q1 2026.

• For the quarter ending Q1 2026, Interest Expenses rose 22.52% year-over-year to $223.6 million; the trailing twelve-month figure through Mar 2026 stood at $223.6 million (up 22.52% YoY), and the FY2025 full-year result was $307.7 million, up 36.43% from the prior year.
• Interest Expenses improved to $223.6 million in Q1 2026, from $6.7 million in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $223.6 million in Q1 2026 to a low of -$198.9 million in Q1 2022.
• A 5-year average of $70.0 million and a median of $160.6 million in 2024 frame the typical range for Interest Expenses.
• Across the five-year window, Interest Expenses slumped 82.0% in 2023 and soared 729.94% in 2025, its largest moves.
• Tracing RPRX's Interest Expenses over 5 years: stood at $18.5 million in 2022, then tumbled by 82.0% to $3.3 million in 2023, then tumbled by 75.8% to $805000.0 in 2024, then jumped by 729.94% to $6.7 million in 2025, then soared by 3246.8% to $223.6 million in 2026.
• Business Quant data shows RPRX's Interest Expenses at $223.6 million in Q1 2026, $6.7 million in Q4 2025, and $79.6 million in Q3 2025.